drugset / Trial / NCT00413218

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

NCT00413218

Phase 3 Completed 450 enrolled Astellas Pharma Inc Basilea Pharmaceutica · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.

Timeline

Start
2007-03-08
Primary completion
2015-03-03
Completion
2015-03-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Caspofungin Other / unclassified 50 mg Intravenous
Comparator Caspofungin Other / unclassified 70 mg Intravenous
Subject Isavuconazole Small molecule 200 mg Intravenous
Comparator Voriconazole Small molecule 200 mg Intravenous

Indications